GSK Enters into Collaboration with Cambridge University on Kidney and Respiratory Disease
Tuesday, October 22, 2024
GSK has announced a £50 million investment in a five-year partnership with the University of Cambridge and Cambridge University Hospitals.
Chronic kidney disease impacts around 850 million people worldwide, often leading to end-stage disease, while chronic respiratory conditions affect roughly 545 million individuals. Current treatments like dialysis or transplants can severely affect patients' quality of life.
The project will target chronic respiratory and kidney diseases, both of which affect millions globally.
The initiative, named the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), aims to accelerate research and development in immune-related diseases, building on the existing relationship between GSK and the university.
This collaboration will focus on finding more precise treatments for respiratory and kidney diseases by improving the understanding of disease mechanisms, patient responses to therapies, and the development of translational biomarkers.
The CG-TIC will adopt a translational approach by integrating patient data with artificial intelligence (AI) and machine learning (ML) techniques.
The research will focus on hard-to-treat conditions affecting the lungs and kidneys, with the ultimate goal of discovering and developing new therapies. The collaboration will be based at the Cambridge Biomedical Campus, which brings together academia, healthcare, and industry, providing an ideal environment for translational research.
The University of Cambridge, situated within Europe’s leading life sciences cluster, will play a key role in driving this research, along with Cambridge University Hospitals and the Royal Papworth Hospital, a specialist heart and lung facility.
The partnership highlights the UK’s strengths in life sciences, with AI expected to help advance treatment options for immune-related diseases, potentially benefiting patients both in the UK and globally.
CG-TIC will be co-led by GSK's VP of Clinical Research, Nicolas Wisniacki, and Professor David Thomas from the Cambridge Institute for Therapeutic Immunology and Infectious Diseases. The collaboration aims to improve patient outcomes and contribute to the development of future therapies.
Source: gsk.com
